Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
暂无分享,去创建一个
J. Carles | E. Gallardo | B. Mellado | J. Albanell | J. Bellmunt | J. Pérez-Gracia | D. Castellano | C. Prior | A. Calvo | P. Maroto | J. González-Larriba | G. Aguilar | X. Villanueva